key: cord-0755737-i2f2uzk4 authors: Sharma, Vineet; Rai, Himanshu; Gautam, Dev N. S.; Prajapati, Pradeep K.; Sharma, Rohit title: Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant date: 2022-02-03 journal: J Med Virol DOI: 10.1002/jmv.27626 sha: 49dee7dd5b31d12a3b7ef73db7e40ad9c9cc5ff6 doc_id: 755737 cord_uid: i2f2uzk4 COVID's Omicron variant has sparked a slew of concerns across the globe. This review aims to provide a brief overview of what we know about the Omicron variant right now. The new variant has been discovered in 149 countries across all six World Health Organization (WHO) regions since its discovery in South Africa on November 24, 2021 and became the dominant variant in the country in less than 3 weeks. The WHO has warned that the B.1.1.529 variant is spreading at an unprecedented rate, and has urged countries to prepare for the worst. Over the course of this time, researchers from Africa and around the world have uncovered a wealth of information about the virus's epidemiology and biological properties. Case numbers are increasing exponentially in hard‐hit areas such as South Africa, United Kingdom, and USA (overtaking the delta variant), implying that the variant is highly transmissible. Initial research has provided some insights into the efficacy of vaccines against the Omicron variant and whether it produces major illness, however, much remains unknown, and additional work is needed to investigate what the initial reports represent in real‐world situations. The Omicron variant multiplies about 70 times faster than the delta variant inside human respiratory tract tissue, according to researchers at the University of Hong Kong. 4, 5 The variant also reaches higher levels in the tissue, compared with delta, 48 h after infection. Garcia-Beltran and his colleagues also suggests Omicron is more infectious than delta. 6, 7 The symptoms appeared to be similar to that of other coronavirus variants. The Omicron variant of the coronavirus continues to spread throughout the world with symptoms of runny nose, headache, fatigue (either mild or severe), sneezing, and sore throatlike symptoms in infected people ( Figure 2 ). 8 The first genome which is now known as the Omicron variant was The lineage was designated as a VOC due to the unique cluster, which was epidemiologically associated with an increase in cases in Gauteng, and the settings of mutations, many of which had previously been linked to immune escape and advice by the Technical Advisory The transmission rate, immune evasion, and the proportions of people who experience serious diseases and die are all useful parameters for determining how the variant will affect the population. 9, 10 The findings for each of these parameters are discussed in detail in the following. In silico analysis revealed that the Omicron SARS-CoV-2 variant spike protein has a higher affinity for the human ACE2 receptor. 11 Omicron's spike protein had at least 30 amino acid substitutions, three small deletions, and one small insertion. 12 Omicron clings to cells more tightly, making them more resistant to antibodies. When the spike grabs onto a cell-surface protein called angiotensin-converting enzyme (ACE2), molecular interactions were discovered using computational methods of the spike protein on Omicron's surface ( Figure 4) . 13, 14 There are two parts to the immune system. Antibodies recognize and bind proteins on microorganisms' surfaces, and neutralize them. T cells, which can recognize and kill virus-infected cells, are involved in the second type of infection. The antibody-mediated response is thought to determine the initial barrier of infection, whereas the cellular response is crucial in the progression of disease severity in COVID-19. 15 Antibodies and are the mainstays of Omicron's evidence. 16 The Omicron variant has approximately 32 mutations in the spike protein, most of which have been linked to antibody-binding sites, The amount and quality of these interactions indicated that the Omicron RBD domain is more effective at binding to receptors. 22 In the Omicron variant, the RBD of Spike has 15 mutations. The ACE2 protein binds to mutated residues 2.5 times stronger. The binding domain's total charge shifts to a positive value. Omicron RBD and ACE2 have a significantly more relaxed dynamic in their complex. 23 The omicron variant's perplexing mutational sequence combines contradictory characteristics that may reduce (virological properties) or increase (immunological escape) the variant's transmission in the human population. Omicron is predicted to be less infective than delta due to an irregular distribution of its electrostatic potential and a defect in the S1-S2 cleavage. 24 In Omicron RBD, the S477N mutation has also been found in B.1.620. S477N has been shown to improve RBD's affinity for hACE2. 25 Han et al. discovered that N477, but not S477, produces an H-bond with S19 from hACE2 to improve Omicron RBD binding to hACE2. E484Q mutation was found in Kappa variants, while E484K mutation was found in Beta, Gamma, Zeta, Eta, and Theta variants. 26, 27 In the case of the Omicron variant, E484 became A484. In hACE2, E484 of the RBD prototype forms a weak contact with K31. The side chain is too short to make contact with hACE2, leading to decreased binding. Both Q493K and Q498H enhance SARS-CoV-2 RBD-binding affinity to hACE2. 28 Both Q493 and Q498 in the Omicron RBD-hACE2 complex were replaced with arginine (R), a positively charged amino acid, and R493 and R498 construct salt bridges with E35 and D38, respectively. Among the various naturally occurring mutations, the E484K mutation, which is carried by several variants and could potentially increase receptor-binding affinity while reducing immune response, has raised serious concerns. Wang et al. found that the E484K mutation improves RBD-binding affinity to the hACE2 receptor, implying greater transmissibility of E484Kcontaining variants. However, RBD-binding affinity to the studied neutralizing antibodies/nanobodies is reduced, implying that these antibodies/nanobodies are less effective. 29 wild type) enhanced binding to cellular polyanionic receptors. This finding sets the foundation for the development of targeted drugs. 37 The RBD of the Omicron variant has 15 mutations, with four of them (K417N, Q493R, N501Y, and Y505H) affecting nine key residues and potentially increasing the virus's ability to bind to hACE2 and infectivity. 38 The N501Y mutation, which has previously been identified in the Beta and Gamma variants of the RBD, is a common mutation. S protein with the N501Y mutation has a ninefold higher affinity for the hACE2 receptor than S protein without the mutation. 39, 40 Multiple complex structures of SARS-CoV-2 RBD-hACE2 possessing N501Y substitution show that Y501 forms π-π stacking interaction with Y41 and forms H-bonds with K353 of hACE2. 41, 42 Notably, Q498R and N501Y mutations of Omicron RBD were previously observed during in vitro evolution, which exhibited 600-fold higher affinity with hACE2. 43 44 A few substituted residues in the Omicron RBD-hACE2 complex reduce the binding interactions between RBD and hACE2, whereas others increase it. Omicron RBDs with the K417N mutation were also found in Beta, Gamma, and even some Delta lineage RBDs. 26 Omicron has accumulated a number of mutations, including S477N, Q498R, and N501Y, which have previously been linked to increased ACE2 receptor binding, 45 potentially improving viral infectivity in host cells. Omicron has a number of novel mutations in or near the NTD, RBD, RBM, furin cleavage site, and S2 domains, which are thought to affect ACE2 binding and/or antibody binding based on previous research on spike protein-ACE2 or antibody interactions. 46 As a result, the Omicron variant could be more infectious or vaccine resistant than other VOCs. Omotuyi et al. 47 showed that Omicron is more transmissible and interacts less efficiently with neutralizing convalescent monoclonal antibody, which has implications for transmissibility if other mutations in the S protein induce cell fusion and viral entry. 47 However, the change to basic amino acids improved the transmissibility of the S-RBD Omicron mutant. 48 One other important parameter of consideration is the rate of transmission, which can help determine how quickly a variant spread in a given area and is crucial in developing testing as well as management strategies, including hospitalization. The doubling time is a useful estimate for determining the rate of transmission. South Africa, the United Kingdom, and Denmark have all provided preliminary data in this regard. According to data from African countries, Omicron variant is more transmissible than Delta. The titers of vaccinated individuals' sera to neutralize Omicron were much lower than any of the other variants studied. 49 Omicron was found to have a significant ability to evade immunity from previous infections with other variants or vaccination. 50 In addition, Omicron infected people who were fully vaccinated as well as those who had additional booster shots. 51 The reproduction number of Omicron was 4.2 times greater than that of the Delta variant based on the frequencies of nucleotide sequences of Omicron in Gauteng province, South Africa. 52 Ito et al. 53 found that the effective reproduction number of Omicron is 3.19 times greater than that of Delta under the same epidemiological conditions in Denmark. 53 week, from 0.4% to 2.9%, according to the Centers for Disease Control and Prevention. 57 In England, the chance of exposure to the omicron variant to another family member is three times greater than the risk of spreading the delta variant. 58 Some other key consideration for public health is disease severity, which is presumably the most challenging to properly estimate because disease severity and deaths occur late in the phase of illness, making accurate assessment time-consuming. 59 There could also be biases in the data, such as demographics, reinfections, or vaccination, making the findings nongeneralizable to other settings. 60 Among these constraints, beginning and preliminary figures from South Africa suggest that the proportion of Omicron variant patients requiring hospitalization in Gauteng province is much lower than in previous waves. 6 Oxygen demands and Intensive Care Unit admissions have both shown similar patterns. 61 While this is a positive aspect, a reasonably high rate of transmission could quickly exhaust existing healthcare ability, resulting in more deaths than predicted. Such healthcare stress may also lead to an increase in mortalities that are not linked to COVID-19. 62 Omicron multiplies 70 times faster in tissues that line airway passages than the earlier Delta variant, potentially facilitating person-to-person spread, according to the researchers. However, Omicron replicates 10 times slower in lung tissues than the original coronavirus, which could contribute to less severe illness. 12 Amidst increased infectivity and transmissibility, Otaki et al. 63 found that the Omicron variant has developed to have greater antigenicity as well as less virulence in humans. The broadly used reverse-transcriptase polymerase chain reaction (RT-PCR) test for diagnosing SARS-CoV-2 infectious diseases uses primers that bind to the virus's genome to amplify a specific genomic region. A typical RT-PCR kit contains two or more sets of primers that target the genome at two or more genes to improve diagnostic sensitivity and specificity. 64 Mutations in the virus genome, which may be where the primers bind by chance, could render these primers ineffective. This is referred to as a dropout or target failure. 65 This would usually not affect the diagnosis because the other sites would continue to function normally. One of the mutations in the Omicron variant is right at the primer binding site, which is targeted by some of the most widely used kits around the world. As a result of the Omicron variant, the spike primers will not work properly. This is known as a Spike Gene Target Failure, or S-dropout, and it is been used as a surrogate for Omicron variants in surveillance. 66 The important thing to remember is that the S-dropout only applies to Omicron's BA.1 cluster; the BA.2 cluster, which makes up a tiny fraction of Omicron, does not cause S-dropout and thus may be overlooked. This also emphasizes the significance of genomic surveillance to determine accurate surveillance assessments. 67 F I G U R E 5 Comparison of COVID-19 variants and its basic reproductive number SHARMA ET AL. | 1881 9 | VACCINES In humans, the severity of the disease is determined not only by virus replication but also by each individual's immune response to the infection, which can sometimes progress to life-threatening inflammation. 68 However, if the virus itself is less harmful to humans, a highly infectious virus can infect a more serious disease and death by infecting a large number of people. 69 As a result, when combined with current studies indicating that the Omicron variant can partially evade vaccine and infection-induced immunity, the overall threat posed by the Omicron variant is likely to be significant. So many studies have suggested that T cells in people who have been vaccinated can mount a strong defense against the variant, which could help prevent severity of disease, hospitalization, and death. 70, 71 Scientists are concerned that the mutations in the variant could allow it to avoid some of the defensive antibodies produced by Covid vaccines. 72 Initial laboratory research suggests that it may be somewhat resistant to vaccines, though it is unlikely to be completely immune. Two shots of the Pfizer-BioNTech vaccine were found to be 70% effective in preventing hospitalization from infection with the omicron variant, compared to 90% protection against hospitalization from the delta variant, according to South Africa's leading healthcare administrator. 73 Based on laboratory studies, Pfizer released a statement that a third with the Pfizer vaccine. Pfizer claims in a recent press release that three doses provide significant protection, but there is no evidence to back up this claim. 77 The spread of SARS-CoV-2 Omicron variant has caused concern among cancer patients, according to Valanparambil et al. Nonsmall cell lung cancer patients had lower binding and live-virusneutralizing antibody titers to SARS-CoV-2 mRNA vaccines than healthy vaccines, with significantly decreased live-virus neutralization of the Delta and Omicron variants than the wild-type strain. 78 The neutralizing potential of vaccine-induced and hybrid immunity-induced antibodies is significantly reduced in the Omicron variant. This could justify immune escape and high transmission despite extensive vaccination coverage. 79 The BNT162b2 vaccine's third dosage (booster) may boost the level of cross-neutralizing antibodies to the omicron variant. 80 10 | SILVER LINING Preliminary evidence suggests that people who have achieved hybrid immunity (infection plus vaccination) tend to be well protected against severe disease and death. 81 According to preliminary data from South Africa, the proportion of infected patients who need to be hospitalized is lower than in previous waves. While this does not necessarily imply that the variant is "milder" than other variants, it does suggest that populations similar to South Africa's young and with a high number of previous infections may be less influenced at this time. 6 The data show that vaccines do protect against severe death and disease, and therefore urgent need is to vaccinate as many people as possible, particularly those in high-risk groups, with two doses of vaccines. 82, 83 With such a high rate of transmission, even a small number of patients' hospitalization can put a huge strain on available resources, both for testing and for providing care to those in need. As a result, measures to slow transmission through coordinated public health strategies must be designed and executed ahead of time, minimizing the impact of such interventions on livelihoods. [84] [85] [86] The present crisis also necessitates a strong emphasis on tried-andtrue prevention strategies. A growing body of evidence suggests that nonpharmacological interventions, such as masks and ventilation, are effective, despite their underappreciation. There is also compelling evidence that masks, particularly high-quality masks (FFP2/N95), are highly effective in preventing infection. 87 Given the evidence of a high rate of transmission, it is critical to consider better safeguards to prevent vulnerable populations, such as those over 60, those with multiple comorbidities, and those on immunosuppression, with better masks. 88, 89 Likewise, the significance of ventilation and social distance cannot be overstated, particularly in situations where a huge number of people are probably to congregate during the festive and wedding season. The primary focus on ventilation in places where numerous footfalls are expected, such as schools, government offices, and wedding halls, would go a long way toward limiting transmission during the season. 90, 91 Molecular surveillance methods, such as whole-genome sequencing and the use of spike-dropouts as surrogates for assessing prevalence, are extremely useful in determining the prevalence in communities, assessing growth, and preparing healthcare systems to manage the onslaught of cases well ahead of time. 92 Omicron was discovered in South Africa on November 24, 2021, and it only took 3 weeks for it to become the dominant variant in the country. It is also on track to supplant the delta variant and take over as the dominant variant in the United Kingdom. The majority of early research indicates that the omicron variant is more contagious than previous strains of the coronavirus, but a definitive picture of its transmissibility is still unknown. Cases in hard-hit areas, such as South Africa and the United Kingdom, are increasing at an exponential rate, implying that the variant is highly transmissible. The new evidence on the omicron variant provides far too little solace. The rapid spread of the Omicron variant is likely to put public health systems to the test, particularly their ability to plan and implement strategies ahead of time, as well as their ability to respond efficiently and quickly. It is probably the best time for general public to get their vaccines, pull up their masks, let a lot of fresh air into their rooms, and avoid crowds. It is always preferable to be safe rather than sorry. Breakthrough infections have been seen in patients who have been vaccinated but have become infected afterward, according to global data. However, the severity of the infection is significantly reduced after vaccination. The mutations may aid in the spread of the variant and allow it to evade specific antibodies produced by vaccines or natural immunity resulting from past infections. Omicron is also a warm-up for the next pandemic. The task at hand is to detect, track, and slow the spread of a health threat (epidemics which are beyond comprehension.). This is the type of work that will be required to avert the next pandemic outbreak. SARS-CoV-2 B.1.1.529 (Omicron) variant-United States Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark International risk of SARS-CoV-2 Omicron variant importations originating in South Africa Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. medRxiv Tracking of variants. GISAID. 2021. Accessed mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant Covid-19: runny nose, headache, and fatigue are commonest symptoms of omicron, early data show The newly detected B.1.1.529 (Omicron) variant of SARS-CoV-2 with multiple mutations: implications for transmission, diagnostics, therapeutics, and immune evasion SARS-CoV-2 Omicron variant: characteristics and prevention Omicron SARS-CoV-2 variant spike protein shows an increased affinity to the human ACE2 receptor: an in silico analysis Science brief: omicron (B.1.1.529) variant. Centers for Disease Control and Prevention (CDC). 2021 Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces SARS-CoV-2, COVID-19 and the aging immune system A critical analysis of the SARS-CoV-2 (COVID-19) pandemic, emerging variants, therapeutic interventions, and vaccination strategies A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters Plasma neutralization properties of the SARS-CoV-2 Omicron variant COV-BOOST: evidence to support rapid booster deployment COVID-19 vaccine strategies must focus on severe disease and global equity Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert Structural modeling of Omicron spike protein and its complex with human ACE-2 receptor: molecular basis for high transmissibility of the virus Scanning the RBD-ACE2 molecular interactions in Omicron variant The puzzling mutational landscape of the SARS-2-variant Omicron Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2 Receptor binding and complex structures of human ACE2 to spike RBD from Omicron and Delta SARS-CoV-2 Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition Emergence of SARS-CoV-2 spike protein escape mutation Q493R after treatment for COVID-19 Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2 Genomic perspectives on the emerging SARS-CoV-2 Omicron variant Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation Charge matters: mutations in Omicron variant favor binding to cells Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein Effectiveness of COVID-19 vaccines against variants of concern The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: binding free energy calculation studies Sequence analysis of the emerging Sars-CoV-2 variant Omicron in South Africa SARS-CoV-2 variants, spike mutations and immune escape SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa Breakthrough infections with SARS-CoV-2 Omicron variant despite booster dose of mRNA vaccine Relative reproduction number of SARS-CoV-2 Omicron (B.1.1.529) compared with Delta variant in South Africa Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark Projected epidemiological consequences of the Omicron SARS-CoV-2 variant in England Omicron Impact in India: an early analysis of the ongoing COVID-19 third wave Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic Accessed SARS-CoV-2 variants of concern and variants under investigation in England. UK Health Security Agency (UHSA) Potential factors for prediction of disease severity of COVID-19 patients Herd immunity: understanding COVID-19 Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients Nonself mutations in the spike protein suggest an increase in the antigenicity and a decrease in the virulence of the Omicron variant of SARS-CoV-2 A coming wave: suicide and gender after COVID-19 Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in SARS-CoV-2 genomic variations associated with mortality rate of COVID-19 PCR performance in the SARS-CoV-2 Omicron variant of concern The first two imported cases of SARS-CoV-2 Omicron variant-Tianjin Municipality Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention How bad is Omicron? What scientists know so far Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals Omicron is supercharging the COVID vaccine booster debate Predicted symptomatic effectiveness of Pfizer-BioNTech BNT162b2 vaccine against Omicron variant of SARS-CoV-2 Covid-19: do vaccines work against Omicron-and other questions answered Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern Sub-optimal neutralisation of Omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 infection plus vaccine (hybrid immunity) post 6-months SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study Crossing the Rubicon: a fine line between waiting and vaccinating adolescents against COVID-19 The impact of first and second wave of the COVID-19 pandemic in society: comparative analysis to support control measures to cope with negative effects of future infectious diseases Impact of US vaccination strategy on COVID-19 wave dynamics Government responses and COVID-19 deaths: global evidence across multiple pandemic waves The COVID-19 pandemic and N95 masks: reusability and decontamination methods Clinical challenges in cancer patients with COVID-19: aging, immunosuppression, and comorbidities comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission Human exposure to respiratory aerosols in a ventilated room: effects of ventilation condition, emission mode, and social distancing The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology The authors declare that there are no conflict of interests. Not applicable.